Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.60 |
| ▸ | SLC2A9 | Q9NRM0 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735901 | 0.90 | SLC22A12 (0.58) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL28666334 | 0.89 | SLC22A12 (0.61) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL10177047 | 0.89 | SLC22A12 (0.63) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL249022 | 0.88 | SLC22A12 (0.78) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL12516448 | 0.88 | SLC22A12 (0.60) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL879017 | 0.88 | SLC22A12 (0.77) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL28145752 | 0.87 | SLC22A12 (0.62) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL13812743 | 0.87 | SLC22A12 (0.63) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL10008373 | 0.86 | SLC22A12 (0.62) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL11915751 | 0.84 | SLC22A12 (0.71) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279188-B1 | AXIALLY CHIRAL ISOMERS, AND PREPARATION METHODS THEREFOR AND PHARMACEUTICAL USES THEREOF | MEDSHINE DISCOVERY INC (CN) | 2020-09-09 | — | — | EP | disclosed |
| US-20200062720-A1 | NOVEL PREPARATION METHOD FOR ANTI-GOUT DRUG LESINURAD, AND KEY INTERMEDIATE THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3281941-B1 | PROCESS FOR PREPARING 2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ZENTIVA KS (CZ) | 2019-07-24 | — | — | EP | disclosed |
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | APOTEX INC. (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190111028-A1 | Polymorphic Forms of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-ylthio)Acetic Acid and Uses Thereof | ARDEA BIOSCIENCES INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190111028-A1 | Polymorphic Forms of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-ylthio)Acetic Acid and Uses Thereof | ARDEA BIOSCIENCES INC. | 2019-04-18 | — | — | US | disclosed |
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2135608-A1 | S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2135608-A1 | S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009070740-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C19 1696/4885CYP2C9 1526/4885 |
| US-10183012-B2 | Compounds and compositions and methods of use | XDH, PON1, OAT | SLC22A12 815/4885CYP2C19 905/4885CYP2C9 762/4885 |
| US-20190111028-A1 | Polymorphic Forms of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-ylthio)Acetic Acid and Uses Thereof | NAT1, CYP2A13, CYP4B1 | SLC22A12 986/4885CYP2C19 40/4885CYP2C9 83/4885 |
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | LSS, SQOR, PGD | SLC22A12 4221/4885CYP2C19 55/4885CYP2C9 25/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | SLC22A12 1536/4885CYP2C19 660/4885CYP2C9 381/4885 |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C19 1898/4885CYP2C9 1309/4885 |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C19 1696/4885CYP2C9 1526/4885 |
| US-20200062720-A1 | NOVEL PREPARATION METHOD FOR ANTI-GOUT DRUG LESINURAD, AND KEY INTERMEDIATE THEREOF | TXNRD3, TXNRD1, CBR3 | SLC22A12 2314/4885CYP2C19 992/4885CYP2C9 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.